The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle in reducing conjunctival hyperemia and preventing pterygium progression in eyes with pterygia.
The objective is to evaluate the safety and efficacy of low dose and high dose CBT-001 eye drop dosed twice daily for 24 months compared to vehicle in reducing conjunctival hyperemia and preventing pterygium progression in eyes with pterygia.
A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
-
Cornea and Cataract Consultants of Arizona, Phoenix, Arizona, United States, 85032
Walman Eye Center, Sun City, Arizona, United States, 83531
Bakersfield Eye Institute, Bakersfield, California, United States, 93308
West Coast Eye Institute, Bakersfield, California, United States, 93311
Global Research Mangement, Glendale, California, United States, 91204
Inland Eye Specialists, Hemet, California, United States, 92545
Shultz Chang Vision, Northridge, California, United States, 91325
Santa Barbara Eye Care, Santa Barbara, California, United States, 93105
Bruce A. Segal, MD, Delray Beach, Florida, United States, 33484
International Research Center, Tampa, Florida, United States, 33603
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
12 Years to
ALL
No
Cloudbreak Therapeutics, LLC,
2026-12-31